NASDAQ:MRUS - Merus Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.70 +0.55 (+3.63 %)
(As of 04/21/2019 03:01 AM ET)
Previous Close$15.70
Today's Range$15.03 - $15.97
52-Week Range$11.00 - $26.74
Volume32,741 shs
Average Volume31,257 shs
Market Capitalization$357.19 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.06
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.14 million
Book Value$4.77 per share

Profitability

Net Income$-28,660,000.00

Miscellaneous

Employees92
Market Cap$357.19 million
Next Earnings Date7/25/2019 (Estimated)
OptionableNot Optionable

Merus (NASDAQ:MRUS) Frequently Asked Questions

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

When is Merus' next earnings date?

Merus is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Merus.

What price target have analysts set for MRUS?

5 equities research analysts have issued 12-month price objectives for Merus' stock. Their predictions range from $16.00 to $35.00. On average, they anticipate Merus' stock price to reach $24.80 in the next twelve months. This suggests a possible upside of 58.0% from the stock's current price. View Analyst Price Targets for Merus.

What is the consensus analysts' recommendation for Merus?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

Has Merus been receiving favorable news coverage?

News headlines about MRUS stock have trended positive on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merus earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

Who are Merus' key executives?

Merus' management team includes the folowing people:
  • Dr. Ton Logtenberg, Pres, CEO & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 54)
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $15.70.

How big of a company is Merus?

Merus has a market capitalization of $357.19 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 92 workers across the globe.

What is Merus' official website?

The official website for Merus is http://www.merus.nl.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]


MarketBeat Community Rating for Merus (NASDAQ MRUS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel